Kim combines a pharmaceutical University background with vast experience in Life Sciences venture capital and investment banking. In the past decade, she has been involved in the early-stage development of a molecular diagnostics company SkylineDx, focusing mainly on corporate development activities. Simultaneously she evaluated biotech investment opportunities for the Van Herk portfolio. Prior to ATAI, Kim was part of a European focused investment banking team at NIBC Bank focusing on M&A and Equity Capital Market transactions of biotech and medtech companies.
Kim holds a BSc in Science and Innovation Management and a MSc in Drug Innovation (Pharmaceutical Sciences) from Utrecht University, NL.